Augmented T cell activation and immunity by CD40 ligation [8] and immune checkpoint blockade [3], and developing CLL vaccines [9, 10] are under clinical investigation, which provide alternative options for CLL immunotherapy. The gene discussed is CD40; the disease is B-cell chronic lymphocytic leukemia.